41 related articles for article (PubMed ID: 34020361)
1. Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.
Oštrbenk Valenčak A; Bertram A; Gröning A; Poljak M
J Clin Virol; 2021 Jul; 140():104851. PubMed ID: 34020361
[TBL] [Abstract][Full Text] [Related]
2. Genotype, cervical intraepithelial neoplasia, and type-specific cervical intraepithelial neoplasia distributions in hrHPV+ cases referred to colposcopy: A multicenter study of Chinese mainland women.
Chen M; Ye Z; Wang H; Cui X; Seery S; Wu A; Xue P; Qiao Y
J Med Virol; 2024 Mar; 96(3):e29475. PubMed ID: 38415472
[TBL] [Abstract][Full Text] [Related]
3. Performance of urine samples compared to cervical samples for detection of precancer lesions among HPV-positive women attending colposcopy clinic in Mexico City.
Meneses-León J; Hernández-Salazar S; Torres-Ibarra L; Hernández-López R; Rivera-Paredez B; Robles-Rivera K; Lazcano-Ponce E; García-Vera A; Godínez-Pérez M; León-Maldonado L; Salmerón J
Cancer Causes Control; 2024 Jun; 35(6):935-942. PubMed ID: 38368574
[TBL] [Abstract][Full Text] [Related]
4. The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test.
Schiffman M; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Apple R; Aldrich C; Erlich HA; Tam T; Befano B; Burk RD; Castle PE
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1304-10. PubMed ID: 26088703
[TBL] [Abstract][Full Text] [Related]
5. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening.
Arbyn M; Simon M; Peeters E; Xu L; Meijer CJLM; Berkhof J; Cuschieri K; Bonde J; Ostrbenk Vanlencak A; Zhao FH; Rezhake R; Gultekin M; Dillner J; de Sanjosé S; Canfell K; Hillemanns P; Almonte M; Wentzensen N; Poljak M
Clin Microbiol Infect; 2021 Aug; 27(8):1083-1095. PubMed ID: 33975008
[TBL] [Abstract][Full Text] [Related]
6. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
7. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
[TBL] [Abstract][Full Text] [Related]
8. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
[TBL] [Abstract][Full Text] [Related]
9. HPV genotype-specific distribution and attributable risk in cervical intraepithelial neoplasia in a referral population with a history of LSIL.
Ratnam S; Jang D; Alaghehbandan R; Gilbert L; Xu Y; Wang W; Andrews P; Green A; Speicher DJ; Chernesky M
Cancer Biomark; 2023; 38(4):433-442. PubMed ID: 37980645
[TBL] [Abstract][Full Text] [Related]
10. Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States.
Wheeler CM; Torrez-Martinez NE; Torres-Chavolla E; Parvu V; Andrews JC; Du R; Robertson M; Joste NE; Cuzick J;
Am J Obstet Gynecol; 2024 Feb; 230(2):243.e1-243.e11. PubMed ID: 37806613
[TBL] [Abstract][Full Text] [Related]
11. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
Inturrisi F; de Sanjosé S; Desai KT; Dagnall C; Egemen D; Befano B; Rodriguez AC; Jeronimo JA; Zuna RE; Hoffman A; Farhat Nozzari S; Walker JL; Perkins RB; Wentzensen N; Palefsky JM; Schiffman M
Int J Cancer; 2024 Jan; 154(2):241-250. PubMed ID: 37772799
[TBL] [Abstract][Full Text] [Related]
12. AmpFire HPV and ScreenFire RS HPV validation trial.
Hou J; Belinson JL; Du H; Li C; Zhang W; Zhang L; Zhang Y; Qu X; Wu R
Am J Clin Pathol; 2024 Jun; 161(6):535-542. PubMed ID: 38365314
[TBL] [Abstract][Full Text] [Related]
13. Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.
Correa RM; Baena A; Valls J; Colucci MC; Mendoza L; Rol M; Wiesner C; Ferrera A; Fellner MD; González JV; Basiletti JA; Mongelos P; Rodriguez de la Peña M; Saino A; Kasamatsu E; Velarde C; Macavilca N; Martinez S; Venegas G; Calderón A; Rodriguez G; Barrios H; Herrero R; Almonte M; Picconi MA;
PLoS One; 2022; 17(7):e0272205. PubMed ID: 35905130
[TBL] [Abstract][Full Text] [Related]
14. Clinical Accuracy of Alinity m HR HPV Assay on Self- versus Clinician-Taken Samples Using the VALHUDES Protocol.
Latsuzbaia A; Van Keer S; Vanden Broeck D; Weyers S; Donders G; De Sutter P; Tjalma W; Doyen J; Vorsters A; Arbyn M
J Mol Diagn; 2023 Dec; 25(12):957-966. PubMed ID: 37865293
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HR-HPV assay (Abbott).
Node J; Dor F; Puget L; Ramanah R; Cot S; Bibeau F; Di Domizio N; Prétet JL; Lepiller Q
J Med Virol; 2024 Feb; 96(2):e29465. PubMed ID: 38323725
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex HPV28 Assays for High-Risk HPV Detection and Genotyping in Mocked Self-Samples.
Bell M; Verberckmoes B; Devolder J; Vermandere H; Degomme O; Guimarães YM; Godoy LR; Ambrosino E; Cools P; Padalko E
Microbiol Spectr; 2023 Aug; 11(4):e0008123. PubMed ID: 37284753
[TBL] [Abstract][Full Text] [Related]
17. A novel tailed primer nucleic acid test for detection of HPV 16, 18 and 45 DNA at the point of care.
Chang MM; Ma A; Novak EN; Barra M; Kundrod KA; Montealegre JR; Scheurer ME; Castle PE; Schmeler K; Richards-Kortum R
Sci Rep; 2023 Nov; 13(1):20397. PubMed ID: 37989845
[TBL] [Abstract][Full Text] [Related]
18. Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening.
Bellosillo B; Ibáñez R; Roura E; Monfil L; Asensio-Puig L; Álvarez I; Muset M; Florencia Y; Paytubi S; de Andrés-Pablo Á; Calvo S; Serrano-Munné L; Pavón MÁ; Lloveras B
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611001
[TBL] [Abstract][Full Text] [Related]
19. Agreement between Xpert and AmpFire tests for high-risk human papillomavirus among HIV-positive women in Rwanda.
Murangwa A; Desai KT; Gage JC; Murenzi G; Tuyisenge P; Kanyabwisha F; Musafili A; Kubwimana G; Mutesa L; Anastos K; Kim HY; Castle PE
Afr J Lab Med; 2022; 11(1):1827. PubMed ID: 36353194
[TBL] [Abstract][Full Text] [Related]
20. Detection of High-Risk Human Papillomavirus Genotypes Among HIV-Infected Women in Four States in Nigeria.
Okwuraiwe AP; Ogbonne EL; Adeniyi AO; Ihurhe PI; Musa BO; Abe TR; Shodipe OO; Audu RA
Cureus; 2024 Mar; 16(3):e57120. PubMed ID: 38681319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
